Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Certolizumab Pegol MeSH Descriptor Data 2026


MeSH Heading
Certolizumab Pegol
Tree Number(s)
D05.750.741.125
D12.644.541.500.650.250
D12.776.124.486.485.114.224.060.500
D12.776.124.486.485.680.650.250
D12.776.124.790.651.114.224.060.500
D12.776.124.790.651.680.650.250
D12.776.377.715.548.114.224.200.500
D12.776.377.715.548.680.650.250
Unique ID
D000068582
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068582
Scope Note
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
Entry Term(s)
CDP 870
CDP870
Cimzia
Pharm Action
Immunosuppressive Agents
Antirheumatic Agents
Tumor Necrosis Factor Inhibitors
Registry Numbers
UMD07X179E
0
Related Numbers
428863-50-7
See Also
Tumor Necrosis Factor-alpha
Public MeSH Note
2016; CERTILIZUMAB PEGOL was indexed under IMMUNOGLOBULIN FAB FRAGMENTS 2003-2015, POLYETHYLENE GLYCOLS 2003-2015, and under ANTIBODIES, MONOCLONAL, HUMANIZED 2003-2015
History Note
2016 (2003)
Date Introduced
2016/01/01
Last Updated
2021/07/01
Certolizumab Pegol Preferred
CDP870 Narrower
Cimzia Narrower
page delivered in 0.175s